Becker's Healthcare August 16, 2024
Elizabeth Gregerson

Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company’s new drug application.

The remaining workforce, led by senior medical adviser David Hough, MD, will focus on clinical development and FDA engagement, according to an Aug. 15 news...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article